These marketed CAR-T products predominantly target CD19 and BCMA, both of which are expressed in B cells, making them suitable for treating B cell-related malignancies and myeloma due to their limited immune evasion, lack of cross-reactivity in multiple tissues, and stable expression [44, 45]. Here, TNFRSF17 is linked to plasma cell myeloma.